Jana Portnow is an Oncology physician affiliated with City Of Hope National Medical Center. OpenAlex indexes 152 publications with 9,433 citations (h-index 32); ClinicalTrials.gov lists 17 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 Duarte Rd
Duarte, CA 910103012
Telephone
626-471-9200Provider last certified this registry record 28 Oct 2020.
Clinical trials
- Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
Sponsor: City of Hope Medical Center
- Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
Sponsor: City of Hope Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
21.5%Salt solutions21.5%Sodium Chloride100%Part D<11 patientsCancer & immunology
20.1%Aromatase Inhibitor10.4%Anastrozole100%Part D<11 patientsKinase inhibitor9.7%Ibrance100%Part D<11 patientsSensory organs
18.8%Corticosteroid18.8%Dexamethasone100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2006–2025 per NIH RePORTER. The latest:
- Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability
Beckman Research Institute/city of Hope
FY2025$925,385U19CA264512 - Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability
Beckman Research Institute/city of Hope
FY2024$882,648U19CA264512
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Yuman Fong, MD
City Of Hope National Medical Center
Ravi Salgia, MD, PhD
City Of Hope National Medical Center
Stephen Gruber, MD
City Of Hope National Medical Center
Tanya Siddiqi, MD
City Of Hope National Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”